SG Americas Securities LLC Boosts Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

SG Americas Securities LLC raised its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 12.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,866 shares of the company’s stock after purchasing an additional 1,508 shares during the quarter. SG Americas Securities LLC’s holdings in iTeos Therapeutics were worth $106,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of ITOS. nVerses Capital LLC increased its position in iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares in the last quarter. Point72 DIFC Ltd acquired a new position in iTeos Therapeutics during the third quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. grew its stake in iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after buying an additional 2,646 shares during the period. Virtu Financial LLC acquired a new stake in shares of iTeos Therapeutics in the third quarter worth $102,000. Finally, Quest Partners LLC raised its stake in shares of iTeos Therapeutics by 914.7% in the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after acquiring an additional 9,934 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ITOS. Wedbush reaffirmed an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, January 16th. Finally, Wells Fargo & Company lowered their target price on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th.

iTeos Therapeutics Trading Up 1.5 %

ITOS opened at $7.29 on Thursday. iTeos Therapeutics, Inc. has a twelve month low of $7.06 and a twelve month high of $18.75. The firm has a market cap of $266.30 million, a price-to-earnings ratio of -2.31 and a beta of 1.38. The company has a fifty day simple moving average of $7.71 and a 200 day simple moving average of $10.48.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.18) by $0.13. On average, analysts forecast that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. The trade was a 8.27 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.50% of the stock is currently owned by company insiders.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.